ArTS Archivio della ricerca di Trieste
ArTS è il sistema di gestione integrata dei dati della ricerca adottato dall' Università degli Studi di Trieste
EnglishBackground: Cryoglobulinemic vasculitis (CV) related to Hepatitis-B Virus (HBV) is rare and its treatmentis ill-defined.Aims: To describe clinical and treatment characteristics of HBV-related CV patients. In addition, the effi-cacy of treatment with antiviral agent nucleotide (NUC), including Entecavir, Adefovir, and Lamivudine,was explored.Methods: In four Italian centres, 17 HBV-positive CV patients (median age 56 years, range 45–70) wereenrolled.Results: The extrahepatic manifestations were: purpura (100%), arthralgias (71%), peripheral neuropathy(29%), chronic hepatitis (47%), liver cirrhosis (29%), and glomerulonephritis (18%). Mixed cryoglobuline-mias were type II (88%) and type III (12%). The median cryocrit was 3% (range 1–14), rheumatoid factor was200 U/L (range 20–5850), C4 was 12 mg/dl (range 2–31), ALT 71 U/L (range 36–114). All patients wereHBsAg-positive and 80% anti-HbeAg-positive. At enrollment, they were treated with steroids (eight),Entecavir (five), Alpha-IFN (two), Adefovir and Lamivudine (one each). After NUC treatment, no diseaseprogression was observed and, in all patients, HBV-DNA became undetectable. Moreover, a regressionof purpura and a reduction of cryocrit were observed. Four patients died during therapy, two of kidneyfailure and two of liver cirrhosis.Conclusion: NUC therapy appeared to be safe and effective in CV-related HBV.
| Titolo: | Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC | |
| Autori: | ||
| Data di pubblicazione: | 2016 | |
| Rivista: | ||
| Abstract: | Background: Cryoglobulinemic vasculitis (CV) related to Hepatitis-B Virus (HBV) is rare and its treatmentis ill-defined.Aims: To describe clinical and treatment characteristics of HBV-related CV patients. In addition, the effi-cacy of treatment with antiviral agent nucleotide (NUC), including Entecavir, Adefovir, and Lamivudine,was explored.Methods: In four Italian centres, 17 HBV-positive CV patients (median age 56 years, range 45–70) wereenrolled.Results: The extrahepatic manifestations were: purpura (100%), arthralgias (71%), peripheral neuropathy(29%), chronic hepatitis (47%), liver cirrhosis (29%), and glomerulonephritis (18%). Mixed cryoglobuline-mias were type II (88%) and type III (12%). The median cryocrit was 3% (range 1–14), rheumatoid factor was200 U/L (range 20–5850), C4 was 12 mg/dl (range 2–31), ALT 71 U/L (range 36–114). All patients wereHBsAg-positive and 80% anti-HbeAg-positive. At enrollment, they were treated with steroids (eight),Entecavir (five), Alpha-IFN (two), Adefovir and Lamivudine (one each). After NUC treatment, no diseaseprogression was observed and, in all patients, HBV-DNA became undetectable. Moreover, a regressionof purpura and a reduction of cryocrit were observed. Four patients died during therapy, two of kidneyfailure and two of liver cirrhosis.Conclusion: NUC therapy appeared to be safe and effective in CV-related HBV. | |
| Handle: | http://hdl.handle.net/11368/2892944 | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.dld.2016.03.018 | |
| URL: | http://www.sciencedirect.com/science/article/pii/S1590865815303480 | |
| Appare nelle tipologie: | 1.1 Articolo in Rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| 1-s2.0-S1590865815303480-main.pdf | Documento in Versione Editoriale | Digital Rights Management non definito | Administrator Richiedi una copia |
